Dear dupa,

For the last year, I’ve been telling our Senior Reporter Max Bayer that he needs to interview FDA Commissioner Marty Makary. And if you’ve met Max, seen him on our stage or online, you’ll know that he’s been working all of his contacts in Trumpworld to make that happen.

So you can imagine how excited I was when two weeks ago, I got this Slack message about our live event in New York on Thursday that we’re co-hosting with the Financial Times: “MAKARY INNNNN.”

A lot can change in two weeks, can’t it?

I’m writing this on Monday morning, after last week’s reports that the White House had signed off on a plan to fire Makary. As of now, that hasn’t happened, and as of now, we’re still expecting him on Thursday.

Plenty can change between today and then. Makary could be pushed out. He could save his job. We could all still be waiting. What I do know is that Max is expecting to interview him on stage in New York on Thursday afternoon for what will be the must-watch conversation of Makary’s tenure as FDA commissioner.

Assuming no change in plans, Max will ask Makary the tough questions about his future and serving in the volatile politics of Trump’s Washington. And he’ll also ask him about his time leading the FDA, the US’s biotech rivalry with China, rebuilding the agency after DOGE and what he still wants to get done.

If you’re already planning to come on Thursday for the US Pharma and Biotech Summit, I’ll see you there — this is a conversation you won’t want to miss. If you don’t have a ticket yet, there are still a few left, and the rest of our agenda will cover the stunning rise of consumer power in healthcare, the fallout from Trump’s “most favored nation” price policy, a test year for AI and much more.